The Suboxone tooth decay mass tort emerged following the FDA's January 2022 warning about the dental effects of buprenorphine-containing medicines administered by dissolving in the mouth, including Suboxone film (a buprenorphine-naloxone combination used for opioid use disorder treatment). The warning identified severe tooth decay, tooth loss, and related complications as adverse events.
Litigation began in 2023–2024 and is consolidated as MDL 3092 in the Northern District of Ohio. Defendants include Indivior (current Suboxone manufacturer) and Reckitt Benckiser (former owner that spun off Indivior in 2014). Settlement frameworks have not yet emerged.
Highfloor supports light-cadence exploratory flights for firms positioning early in the docket. Bar TV reaching opioid-use-disorder-treatment-population demographics plus search-keyword spend on Suboxone-tooth-decay-specific terms.
- Light-cadence exploratory flights
- Bar TV reaching broader treatment-population demographics
- Search-keyword spend on Suboxone-tooth-decay-specific terms
- January 2022 — FDA warning on dental effects of buprenorphine films
- 2023–2024 — first Suboxone tooth decay lawsuits filed
- 2024 — JPML consolidates to MDL 3092 (N.D. Ohio)
- Distributed broadly — opioid-use-disorder treatment population is geographically distributed